
## Aloysius Ho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7803182/publications.pdf Version: 2024-02-01



Διονείμε Ηο

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 2004, 103, 428-434.  | 0.6 | 171       |
| 2  | CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia, 2007, 21, 1937-1944.  | 3.3 | 147       |
| 3  | Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2006, 108, 2928-2936. | 0.6 | 129       |
| 4  | One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica, 2022, 107, 1045-1053.  | 1.7 | 87        |
| 5  | Eczematoid Graft-vs-Host Disease. Archives of Dermatology, 2007, 143, 1157-62.   | 1.7 | 55        |
| 6  | Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced<br>intensity conditioning hematopoietic stem cell transplants with alemtuzumab. Journal of Medical<br>Virology, 2006, 78, 1560-1563.  | 2.5 | 48        |
| 7  | Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning<br>allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone<br>Marrow Transplantation, 2010, 45, 633-639.   | 1.3 | 47        |
| 8  | Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges. British<br>Journal of Dermatology, 2007, 156, 1032-1038.  | 1.4 | 44        |
| 9  | Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed<br>advanced stage follicular lymphoma. British Journal of Haematology, 2008, 141, 235-243.  | 1.2 | 44        |
| 10 | Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2005, 35, 299-301.   | 1.3 | 42        |
| 11 | Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. Bone Marrow Transplantation, 2020, 55, 1050-1058.   | 1.3 | 42        |
| 12 | Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. British<br>Journal of Haematology, 2007, 137, 374-375.  | 1.2 | 38        |
| 13 | An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 2006, 55, 1017-1024.  | 2.0 | 31        |
| 14 | Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell<br>Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Secondary to<br>Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 111-117.   | 2.0 | 27        |
| 15 | Incidence and management of hepatic venoocclusive disease in 237 patients undergoing<br>reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow<br>Transplantation, 2006, 38, 823-824.   | 1.3 | 26        |
| 16 | Isochromosome of a deleted 20q: a rare but recurrent chromosome abnormality in myelodysplastic syndromes. Cancer Genetics and Cytogenetics, 2005, 156, 154-157.  | 1.0 | 21        |
| 17 | Respiratory virus infection after allogeneic hematopoietic stem cell transplant in a tropical center:<br>Predictive value of the immunodeficiency scoring index. Transplant Infectious Disease, 2017, 19, e12693.  | 0.7 | 18        |
| 18 | Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic<br>stem cell transplantation: association with chronic graft-versus-host disease and improved overall<br>survival. Bone Marrow Transplantation, 2007, 40, 747-752.   | 1.3 | 15        |

ALOYSIUS HO

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Complete response of deep neutrophilic dermatosis associated with myelodysplastic syndrome to 5-azacytidine. British Journal of Dermatology, 2007, 156, 1039-1041.   | 1.4 | 15        |
| 20 | Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200. Blood, 2003, 101, 779-780.   | 0.6 | 9         |
| 21 | Fanconi-Like Syndrome with Negative Chromosomal Breakages Test and High Incidence of<br>Myelodysplasia Blood, 2007, 110, 1681-1681.  | 0.6 | 9         |
| 22 | Donorâ€ŧype fresh frozen plasma is effective in preventing hemolytic reaction in major ABO<br>incompatible allogeneic stem cell transplant. Transfusion, 2019, 59, 335-339.  | 0.8 | 6         |
| 23 | Longâ€ŧerm renal outcome after allogeneic hemopoietic stem cell transplant: A comprehensive analysis<br>of risk factors in an Asian patient population. Clinical Transplantation, 2017, 31, e12920.  | 0.8 | 4         |
| 24 | Outcomes of MDS Patients with Chromosome 7 Abnormalities Treated with 5-Azacytidine Blood, 2007, 110, 1449-1449.   | 0.6 | 4         |
| 25 | Asthmatic adult with marked blood eosinophilia: is it truly asthma?. BMJ Case Reports, 2018, 2018, bcr-2017-222344.  | 0.2 | 2         |
| 26 | Mobilization kinetics of peripheral blood stem cells with rescue plerixafor – real-world experience<br>from a single center. Leukemia and Lymphoma, 2020, 61, 1740-1743.   | 0.6 | 0         |
| 27 | Single Centre Experience of Patients with Haematological Malignancies Admitted to Intensive Care<br>Unit: A Comparative Review of Allogenic Bone Marrow Transplant Data Blood, 2004, 104, 1830-1830.   | 0.6 | 0         |
| 28 | Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Is as Effective in Poor Risk as<br>Standard Risk Acute Myeloid Leukaemia (AML) Blood, 2005, 106, 2901-2901.   | 0.6 | 0         |
| 29 | Improved Disease Free Survival Following Reduced Intensity Conditioned Allogeneic Stem Cell<br>Transplantation Incorporating Alemtuzumab Compared with Autologous Stem Cell Transplantation in<br>Follicular Lymphoma Blood, 2005, 106, 1144-1144. | 0.6 | 0         |